| Announced on | Meeting on |
| Jun 28, 2024 | Aug 21, 2024 |
| Audited Results & Final Dividend | |
| Mar 27, 2024 | May 02, 2024 |
| Quarterly Results | |
| Jan 12, 2024 | Feb 06, 2024 |
| Quarterly Results & Interim Dividend | |
| Sep 27, 2023 | Nov 03, 2023 |
| Quarterly Results | |
| Jul 17, 2023 | Aug 23, 2023 |
| Audited Results & Final Dividend | |
P&G Health - Procter & Gamble Health Share Price
NSE
- Open5,200.00
- High5,238.00
- Low5,192.50
- Prev Close5,203.45
- Volume4,588
- VWAP(₹)5,206.49
P&G Health share price insights
Zero Debt Burden
Company has no debt since last 5 years. (Source: Standalone Financials)Quarterly Topline Performance
Company witnessed QoQ revenue growth of 12.27%, which is highest in the last 3 years. (Source: Standalone Financials)Candle Formations Yesterday
Inverted Hammer was formed for P&G HealthStock Returns vs Nifty Midcap 100
Stock gave a 3 year return of -6.04% as compared to Nifty Midcap 100 which gave a return of 112.53%. (as of last trading session)P&G Health Share Price Update
Procter & Gamble Health Ltd. share price moved up by 0.09% from its previous close of Rs 5,203.45. Procter & Gamble Health Ltd. stock last traded price is 5,207.75
Share Price Value Today/Current/Last 5,207.75 Previous Day 5,203.45
P&G Health Share Price Returns
| 1 Day | 0.09% |
| 1 Month | 0.79% |
| 3 Months | 8.79% |
| 1 Year | 8.98% |
| 3 Years | -6.04% |
| 5 Years | 23.55% |
Key Metrics
| PE Ratio(x) | 43.01 |
| EPS - TTM(₹) | 121.08 |
| MCap(₹ Cr.) | 8,644.54 |
| MCap Rank | 41 |
| PB Ratio(x) | 16.05 |
| Div Yield(%) | 4.99 |
| Face Value(₹) | 10.00 |
| 52W High(₹) | 5,642.85 |
| 52W Low(₹) | 4,636.55 |
| MCap/Sales | 7.28 |
| Beta(1 Month) | 0.56 |
| BV/Share(₹) | 324.25 |
P&G Health Share Recommendations
No Recommendations details available for this stock.
Check out other stock recos.
ADVERTISEMENT
P&G Health News & Analysis
NewsWill the wave of restructuring help? 7 MNC pharma stocks with upside potential of up to 14%
NewsITC among 4 stocks with RSI trending up
NewsTrident, KNR Constructions among 10 stocks with RSI trending up Communication In Respect Of Deduction Of Tax At Source (TDS) On The Amount Of Dividen..
Announcements
ADVERTISEMENT
P&G Health Financials
Consolidated
Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Total Income 286.01 254.75 315.15 310.98 306.64 Total Income Growth (%) 12.27 -19.17 1.34 1.42 -5.91 Total Expenses 262.98 191.88 215.24 222.75 262.34 Total Expenses Growth (%) 37.05 -10.85 -3.37 -15.09 6.15 EBIT 23.03 62.87 99.91 88.23 44.30 EBIT Growth (%) -63.37 -37.07 13.24 99.16 -43.74 Profit after Tax (PAT) 16.78 46.56 72.07 65.57 29.82 PAT Growth (%) -63.96 -35.40 9.91 119.89 -49.62 EBIT Margin (%) 8.05 24.68 31.70 28.37 14.45 Net Profit Margin (%) 5.87 18.28 22.87 21.08 9.72 Basic EPS (₹) 10.11 28.00 43.40 39.50 17.96 All figures in Rs Cr, unless mentioned otherwise
InsightsQuarterly Topline Performance
Company witnessed QoQ revenue growth of 12.27%, which is highest in the last 3 years. (Source: Standalone Financials)Topline Contraction
Sales de-grew by 6.5%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Standalone Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 794.36 1,101.19 893.72 986.16 1,175.74 Total Assets Growth (%) -27.86 23.21 -9.37 -16.12 -33.18 Total Liabilities 256.12 350.30 277.23 282.45 269.40 Total Liabilities Growth (%) -26.89 26.36 -1.85 4.84 22.82 Total Equity 538.24 750.89 616.49 703.71 906.34 Total Equity Growth (%) -28.32 21.80 -12.39 -22.36 -41.15 Current Ratio (x) 2.39 2.62 2.60 3.04 4.21 Total Debt to Equity (x) 0.00 0.00 0.00 0.00 0.00 Contingent Liabilities 0.00 165.48 258.16 244.23 194.70 All figures in Rs Cr, unless mentioned otherwise
InsightsZero Debt Burden
Company has no debt since last 5 years. (Source: Standalone Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities - 236.00 169.52 247.26 235.37 Net Cash used in Investing Activities - -21.50 -25.54 -32.27 164.64 Net Cash flow from Financing Activities - -98.48 -288.63 -386.63 -883.41 Net Cash Flow - 116.02 -144.65 -171.64 -483.40 Closing Cash & Cash Equivalent - 435.42 319.40 464.05 635.69 Closing Cash & Cash Equivalent Growth (%) 0.00 36.32 -31.17 -27.00 -43.22 Total Debt/ CFO (x) - 0.00 0.00 0.00 0.00 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 37.34 30.55 31.22 25.12 28.03 Return on Capital Employed (%) 51.13 39.50 38.57 31.32 37.41 Return on Assets (%) 25.30 20.83 21.54 17.92 21.61 Interest Coverage Ratio (x) 446.71 445.55 668.74 292.60 0.00 Asset Turnover Ratio (x) 1.21 1.23 1.19 102.28 115.31 Price to Earnings (x) 41.84 38.02 36.23 52.63 26.60 Price to Book (x) 15.57 11.60 11.28 13.20 7.45 EV/EBITDA (x) 25.30 24.12 23.59 33.38 15.91 EBITDA Margin (%) 27.93 27.90 25.20 26.18 28.34 InsightsROE Outperforming 5 Year Average
Company delivered ROE of 37.34% in year ending Jun 30, 2024 outperforming its 5 year avg. of 29.98%. (Source: Standalone Financials)
ADVERTISEMENT
Peer Comparison
NAME 1D 1W 1M 3M 1Y 3Y 5Y P&G Health Stock Performance 0.09 -3.08 -0.49 8.23 7.99 -6.04 20.64 Abbott India Stock Performance 0.10 5.11 4.89 15.62 28.20 57.57 230.18 GSK Pharma Stock Performance -1.39 -9.63 2.19 11.54 95.84 82.54 130.23 Pfizer Stock Performance -0.04 -0.31 13.60 30.19 55.11 4.64 105.39 AstraZeneca Stock Performance -1.13 0.51 -7.13 3.07 60.73 117.96 263.03 All values in %
Insights
Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of -6.04% as compared to Nifty Midcap 100 which gave a return of 112.53%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated -6.04% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
Mutual Funds Ownership
MF Ownership as on 31 July 2024
347.97
Amount Invested (in Cr.)
0.58%
% of AUM
0.25
% Change (MoM basis)
168.88
Amount Invested (in Cr.)
1.93%
% of AUM
0.91
% Change (MoM basis)
UTI MNC Direct-G
Equity: Thematic-MNC
126.13
Amount Invested (in Cr.)
3.93%
% of AUM
1.62
% Change (MoM basis)
ADVERTISEMENT
Corporate Actions
Final
600%
Aug 22, 2024
Board Meeting
Audited Results & Final Dividend
Jun 28, 2024
Board Meeting
Quarterly Results
Mar 27, 2024
Announced on Ex-Date Dividend% Jan 26, 2024 Feb 14, 2024 1500% Jan 25, 2024 Feb 14, 2024 500% Aug 24, 2023 Nov 23, 2023 500% Jan 16, 2023 Feb 13, 2023 450% Aug 22, 2024 - 600% Announced on Ex-Date Sep 30, 1991 Nov 05, 1991 Bonus Ratio: 1 share(s) for every 2 shares held Sep 11, 1986 - Bonus Ratio: 3 share(s) for every 5 shares held No Data Available
No Data Available
Announced on Meeting on Aug 24, 2023 Nov 21, 2023 Rs.50.0000 per share(500%)Final Dividend & A.G.M. Apr 10, 2023 May 12, 2023 - Feb 21, 2023 Mar 24, 2023 - Sep 15, 2020 Nov 26, 2020 Book closure from Nov 20, 2020 to Nov 26, 2020 Mar 20, 2019 Apr 02, 2019 -
ADVERTISEMENT
About
Procter & Gamble Health Ltd., incorporated in the year 1967, is a Mid Cap company (having a market cap of Rs 8,644.54 Crore) operating in Pharmaceuticals sector.
Procter & Gamble Health Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue, Scrap and Export Incentives for the year ending 30-Jun-2023.
For the quarter ended 30-06-2024, the company has reported a Standalone Total Income of Rs 286.01 Crore, up 12.27 % from last quarter Total Income of Rs 254.75 Crore and down 6.73 % from last year same quarter Total Income of Rs 306.64 Crore. Company has reported net profit after tax of Rs 16.78 Crore in latest quarter.
The company’s top management includes Mr.Suresh Talwar, Mr.Milind Thatte, Mr.Lokesh Chandak, Mr.Aalok Agrawal, Ms.Seema Sambasivan, Mrs.Rani Jadhav, Mr.S Madhavan, Ms.Zeal Rupani. Company has Haribhakti & Co. LLP as its auditors. As on 30-06-2024, the company has a total of 1.66 Crore shares outstanding.
About P&G Health
Procter & Gamble Health Ltd., incorporated in the year 1967, is a Mid Cap company (having a market cap of Rs 8,644.54 Crore) operating in Pharmaceuticals sector. Procter & Gamble Health Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue, Scrap and Export Incentives for the year ending 30-Jun-2023.For the quarter ended 30-06-2024, the company has reported a Standalone Total Income of Rs 286.01 Crore, up 12.27 % from last quarter Total Income of Rs 254.75 Crore and down 6.73 % from last year same quarter Total Income of Rs 306.64 Crore. Company has reported net profit after tax of Rs 16.78 Crore in latest quarter.The company’s top management includes Mr.Suresh Talwar, Mr.Milind Thatte, Mr.Lokesh Chandak, Mr.Aalok Agrawal, Ms.Seema Sambasivan, Mrs.Rani Jadhav, Mr.S Madhavan, Ms.Zeal Rupani. Company has Haribhakti & Co. LLP as its auditors. As on 30-06-2024, the company has a total of 1.66 Crore shares outstanding.
Industry
Key Indices Listed On
BSE 500, BSE 250 SmallCap Index, BSE SmallCap, BSE Healthcare, BSE 400 MidSmallCap Index
Address
P&G Plaza,Cardinal Gracias Road,Chakala, Andheri (East),Mumbai, Maharashtra - 400099
Executive Leadership
ST
Suresh Talwar
Chairman & Ind.DirectorMT
Milind Thatte
Managing DirectorLC
Lokesh Chandak
Executive Director & CFOAA
Aalok Agrawal
Non Executive DirectorShow More
Auditors
Haribhakti & Co. LLP
Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.